CytoDyn (id:11203 CYDY)
0.120 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 9:30:25 PM)
Exchange closed, opens in 11 hours 59 minutes
About CytoDyn
Market Capitalization 146.38M
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
| Headquarters (address) |
1111 Main Street Vancouver 98660 WA United States |
| Phone | 360 980 8524 |
| Website | https://www.cytodyn.com |
| Employees | 9 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | CYDY |
| Exchange | OTC Markets U.S. |
| Currency | USD |
| 52 week range | 0.110 - 0.420 |
| Market Capitalization | 146.38M |
| P/E trailing | -2.40 |
| P/E forward | -0.667 |
| Price/Book | -1.60 |
| Beta | 0.165 |
| EPS | -0.020 |
| EPS United States (ID:6, base:3402) | 24.23 |